Esperion HSR waiting period cleared for ArchiMed merger; shareholder vote set for July 8

Esperion Therapeutics, Inc.

Hart-Scott-Rodino waiting period expired June 15, 2026, satisfying a key regulatory condition.
Special stockholder meeting to vote on merger adoption scheduled for July 8, 2026 at 8:00 a.m. ET.
Closing remains subject to other customary conditions, including stockholder approval.
Merger with affiliate of ArchiMed SAS was announced May 1, 2026; transaction is pending.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.